Abstract
Background Secondary central nervous system lymphoma (SCNSL) without extra-central nervous system (CNS) involvement is characterized by isolated secondary CNS relapse in malignant lymphoma patients. SCNSL is a rare disease, and no standard treatment has yet been established. Patients and methods To elucidate the clinical characteristics and outcomes of SCNSL, we retrospectively analyzed 12 patients (median age 67 years) in Miyazaki prefecture for the last 5 years. Results The initial histological diagnoses of the patients were diffuse large B-cell lymphoma (DLBCL), mantle-cell lymphoma, and adult T-cell lymphoma in 9, 2, and 1 patient, respectively. We focused on analysis of the 9 SCNSL cases originating from DLBCL. The locations of CNS relapse were the cerebral hemisphere, basal ganglia, and cerebellum in 7, 1, and 1 patient, respectively. Three patients were treated with high-dose methotrexate (HDMTX) therapy; 4 with whole-brain radiation therapy (WBRTX); and 1 with both HD-MTX and WBRTX. The remaining patients were treated with rituximab. Partial remission was achieved in 6 out of 9 patients (67%); the other 3 patients (33%) did not respond to therapy. Median survival of the 9 patients with CNS relapse was 253 days; 6 of the 9 patients survived for more than 6 months. As of March 2011, 2 HD-MTX group patients but none of the WBRTX group patients were alive. Conclusions In this retrospective study, 6 of 9 patients with SCNSL originating from DLBCL survived for more than 6 months. Both HD-MTX and WBRTX had clinical benefits in the treatment of SCNSL.
| Original language | English |
|---|---|
| Pages (from-to) | 336-340 |
| Number of pages | 5 |
| Journal | International Journal of Clinical Oncology |
| Volume | 17 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Aug 1 2012 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Surgery
- Hematology
- Oncology
Cite this
Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture. / Kawano, Noriaki; Ochiai, Hidenobu; Yoshida, Shuro; Yamashita, Kiyoshi; Shide, Kotaro; Shimoda, Haruko; Hidaka, Tomonori; Kubuki, Yoko; Katayose, Keiko; Toyama, Takanori; Kawano, Hiroshi; Matsuoka, Hitoshi; Ishizaki, Junzo; Maeda, Koichi; Satou, Seiichi; Yano, Tatsuhiko; Yamaguchi, Kenichiro; Takenaka, Katsuto; Shimao, Yoshiya; Oshima, Koichi; Ueda, Akira; Shimoda, Kazuya.
In: International Journal of Clinical Oncology, Vol. 17, No. 4, 01.08.2012, p. 336-340.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture
AU - Kawano, Noriaki
AU - Ochiai, Hidenobu
AU - Yoshida, Shuro
AU - Yamashita, Kiyoshi
AU - Shide, Kotaro
AU - Shimoda, Haruko
AU - Hidaka, Tomonori
AU - Kubuki, Yoko
AU - Katayose, Keiko
AU - Toyama, Takanori
AU - Kawano, Hiroshi
AU - Matsuoka, Hitoshi
AU - Ishizaki, Junzo
AU - Maeda, Koichi
AU - Satou, Seiichi
AU - Yano, Tatsuhiko
AU - Yamaguchi, Kenichiro
AU - Takenaka, Katsuto
AU - Shimao, Yoshiya
AU - Oshima, Koichi
AU - Ueda, Akira
AU - Shimoda, Kazuya
PY - 2012/8/1
Y1 - 2012/8/1
N2 - Background Secondary central nervous system lymphoma (SCNSL) without extra-central nervous system (CNS) involvement is characterized by isolated secondary CNS relapse in malignant lymphoma patients. SCNSL is a rare disease, and no standard treatment has yet been established. Patients and methods To elucidate the clinical characteristics and outcomes of SCNSL, we retrospectively analyzed 12 patients (median age 67 years) in Miyazaki prefecture for the last 5 years. Results The initial histological diagnoses of the patients were diffuse large B-cell lymphoma (DLBCL), mantle-cell lymphoma, and adult T-cell lymphoma in 9, 2, and 1 patient, respectively. We focused on analysis of the 9 SCNSL cases originating from DLBCL. The locations of CNS relapse were the cerebral hemisphere, basal ganglia, and cerebellum in 7, 1, and 1 patient, respectively. Three patients were treated with high-dose methotrexate (HDMTX) therapy; 4 with whole-brain radiation therapy (WBRTX); and 1 with both HD-MTX and WBRTX. The remaining patients were treated with rituximab. Partial remission was achieved in 6 out of 9 patients (67%); the other 3 patients (33%) did not respond to therapy. Median survival of the 9 patients with CNS relapse was 253 days; 6 of the 9 patients survived for more than 6 months. As of March 2011, 2 HD-MTX group patients but none of the WBRTX group patients were alive. Conclusions In this retrospective study, 6 of 9 patients with SCNSL originating from DLBCL survived for more than 6 months. Both HD-MTX and WBRTX had clinical benefits in the treatment of SCNSL.
AB - Background Secondary central nervous system lymphoma (SCNSL) without extra-central nervous system (CNS) involvement is characterized by isolated secondary CNS relapse in malignant lymphoma patients. SCNSL is a rare disease, and no standard treatment has yet been established. Patients and methods To elucidate the clinical characteristics and outcomes of SCNSL, we retrospectively analyzed 12 patients (median age 67 years) in Miyazaki prefecture for the last 5 years. Results The initial histological diagnoses of the patients were diffuse large B-cell lymphoma (DLBCL), mantle-cell lymphoma, and adult T-cell lymphoma in 9, 2, and 1 patient, respectively. We focused on analysis of the 9 SCNSL cases originating from DLBCL. The locations of CNS relapse were the cerebral hemisphere, basal ganglia, and cerebellum in 7, 1, and 1 patient, respectively. Three patients were treated with high-dose methotrexate (HDMTX) therapy; 4 with whole-brain radiation therapy (WBRTX); and 1 with both HD-MTX and WBRTX. The remaining patients were treated with rituximab. Partial remission was achieved in 6 out of 9 patients (67%); the other 3 patients (33%) did not respond to therapy. Median survival of the 9 patients with CNS relapse was 253 days; 6 of the 9 patients survived for more than 6 months. As of March 2011, 2 HD-MTX group patients but none of the WBRTX group patients were alive. Conclusions In this retrospective study, 6 of 9 patients with SCNSL originating from DLBCL survived for more than 6 months. Both HD-MTX and WBRTX had clinical benefits in the treatment of SCNSL.
UR - http://www.scopus.com/inward/record.url?scp=84867329304&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867329304&partnerID=8YFLogxK
U2 - 10.1007/s10147-011-0292-5
DO - 10.1007/s10147-011-0292-5
M3 - Article
C2 - 21904968
AN - SCOPUS:84867329304
VL - 17
SP - 336
EP - 340
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
SN - 1341-9625
IS - 4
ER -